
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7609550/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Measles susceptibility in maternal-infant dyads—Bamako, Mali. Vaccine, 2022, 40, 1316-1322.	1.7	1
2	Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VIS649 (Sibeprenlimab), an APRIL-Neutralizing IgG2 Monoclonal Antibody, in Healthy Volunteers. Kidney International Reports, 2022, 7, 993-1003.	0.4	18
3	Altered Gut Microbiome and Fecal Immune Phenotype in Early Preterm Infants With Leaky Gut. Frontiers in Immunology, 2022, 13, 815046.	2.2	10
4	Functional and structural modifications of influenza antibodies during pregnancy. IScience, 2022, 25, 104088.	1.9	7
5	Efficient production of immunologically active Shigella invasion plasmid antigens IpaB and IpaH using a cell-free expression system. Applied Microbiology and Biotechnology, 2022, 106, 401-414.	1.7	5
6	Epithelial and Neutrophil Interactions and Coordinated Response to <i>Shigella</i> in a Human Intestinal Enteroid-Neutrophil Coculture Model. MBio, 2022, 13, .	1.8	8
7	Highly Specialized Carbohydrate Metabolism Capability in <i>Bifidobacterium</i> Strains Associated with Intestinal Barrier Maturation in Early Preterm Infants. MBio, 2022, 13, .	1.8	10
8	Respiratory Syncytial Virus (RSV) Neutralizing Antibodies at Birth Predict Protection from RSV Illness in Infants in the First 3 Months of Life. Clinical Infectious Diseases, 2021, 73, e4421-e4427.	2.9	42
9	Adjustments for oral fluid quality and collection methods improve prediction of circulating tetanus antitoxin: Approaches for correcting antibody concentrations detected in a non-invasive specimen. Vaccine, 2021, 39, 423-430.	1.7	2
10	Low dose recombinant full-length circumsporozoite protein-based Plasmodium falciparum vaccine is well-tolerated and highly immunogenic in phase 1 first-in-human clinical testing. Vaccine, 2021, 39, 1195-1200.	1.7	18
11	Tick extracellular vesicles enable arthropod feeding and promote distinct outcomes of bacterial infection. Nature Communications, 2021, 12, 3696.	5.8	27
12	Human Breast Milk Enhances Intestinal Mucosal Barrier Function and Innate Immunity in a Healthy Pediatric Human Enteroid Model. Frontiers in Cell and Developmental Biology, 2021, 9, 685171.	1.8	16
13	Safety and immunogenicity of Vi-typhoid conjugate vaccine co-administration with routine 9-month vaccination in Burkina Faso: A randomized controlled phase 2 trial. International Journal of Infectious Diseases, 2021, 108, 465-472.	1.5	14
14	Maternal and neonatal immunization in the Americas: The benefits, the hurdles, and the way forward. Vaccine, 2021, 39, B1-B2.	1.7	0
15	Immunogenicity and Efficacy of Live-Attenuated <i>Salmonella</i> Typhimurium Vaccine Candidate CVD 1926 in a Rhesus Macaque Model of Gastroenteritis. Infection and Immunity, 2021, 89, e0008721.	1.0	5
16	Linked vaccination coverage surveys plus serosurveys among Ethiopian toddlers undertaken three years apart to compare coverage and serologic evidence of protection in districts implementing the RED-QI approach. Vaccine, 2021, 39, 5802-5813.	1.7	4
17	Repertoire of Naturally Acquired Maternal Antibodies Transferred to Infants for Protection Against Shigellosis. Frontiers in Immunology, 2021, 12, 725129.	2.2	15
18	A Novel Recombinant Influenza Virus Neuraminidase Vaccine Candidate Stabilized by a Measles Virus Phosphoprotein Tetramerization Domain Provides Robust Protection from Virus Challenge in the Mouse Model. MBio, 2021, 12, e0224121.	1.8	21

#	Article	IF	CITATIONS
19	Functional antibodies as immunological endpoints to evaluate protective immunity against <i>Shigella</i> . Human Vaccines and Immunotherapeutics, 2020, 16, 197-205.	1.4	21
20	Oral Shigella Vaccines. , 2020, , 515-536.		7
21	Overcoming Waning Immunity in Pertussis Vaccines: Workshop of the National Institute of Allergy and Infectious Diseases. Journal of Immunology, 2020, 205, 877-882.	0.4	17
22	Pre-existing Helicobacter pylori serum IgG enhances the vibriocidal antibody response to CVD 103-HgR live oral cholera vaccine in Malian adults. Scientific Reports, 2020, 10, 16871.	1.6	4
23	Evaluation of a standardised Vi poly-l-lysine ELISA for serology of Vi capsular polysaccharide antibodies. Biologicals, 2020, 66, 21-29.	0.5	6
24	The SENIEUR protocol and the efficacy of hepatitis B vaccination in healthy elderly persons by age, gender, and vaccine route. Immunity and Ageing, 2020, 17, 9.	1.8	8
25	Pregnancy level of estradiol attenuated virus-specific humoral immune response in H5N1-infected female mice despite inducing anti-inflammatory protection. Emerging Microbes and Infections, 2019, 8, 1146-1156.	3.0	7
26	Development of a multiple-antigen protein fusion vaccine candidate that confers protection against Bacillus anthracis and Yersinia pestis. PLoS Neglected Tropical Diseases, 2019, 13, e0007644.	1.3	10
27	Maternal Antibodies Elicited by Immunization With an O- Polysaccharide Glycoconjugate Vaccine Protect Infant Mice Against Lethal Salmonella Typhimurium Infection. Frontiers in Immunology, 2019, 10, 2124.	2.2	2
28	mSphere of Influence: the View from the Microbiologists of the Future. MSphere, 2019, 4, .	1.3	0
29	A Combined YopB and LcrV Subunit Vaccine Elicits Protective Immunity againstYersiniaInfection in Adult and Infant Mice. Journal of Immunology, 2019, 202, 2005-2016.	0.4	4
30	Consensus Report on Shigella Controlled Human Infection Model: Immunological Assays. Clinical Infectious Diseases, 2019, 69, S596-S601.	2.9	22
31	A Phase 1 dose escalating study of double mutant heat-labile toxin LTR192G/L211A (dmLT) from Enterotoxigenic Escherichia coli (ETEC) by sublingual or oral immunization. Vaccine, 2019, 37, 602-611.	1.7	24
32	Completion of an Experiment. MSphere, 2018, 3, .	1.3	0
33	Improving Our Understanding of <i>Salmonella enterica</i> Serovar Paratyphi B through the Engineering and Testing of a Live Attenuated Vaccine Strain. MSphere, 2018, 3, .	1.3	7
34	Immunogenicity and efficacy following sequential parenterally-administered doses of Salmonella Enteritidis COPS:FliC glycoconjugates in infant and adult mice. PLoS Neglected Tropical Diseases, 2018, 12, e0006522.	1.3	15
35	Improved Tolerability of a Salmonella enterica Serovar Typhimurium Live-Attenuated Vaccine Strain Achieved by Balancing Inflammatory Potential with Immunogenicity. Infection and Immunity, 2018, 86, .	1.0	9
36	Development of a broad spectrum glycoconjugate vaccine to prevent wound and disseminated infections with Klebsiella pneumoniae and Pseudomonas aeruginosa, PLoS ONE, 2018, 13, e0203143	1.1	67

#	Article	IF	CITATIONS
37	Establishment of the first International Standard for human anti-typhoid capsular Vi polysaccharide IgG. Biologicals, 2018, 56, 29-38.	0.5	20
38	A Novel <i>Shigella</i> Proteome Microarray Discriminates Targets of Human Antibody Reactivity following Oral Vaccination and Experimental Challenge. MSphere, 2018, 3, .	1.3	27
39	Safety and immunogenicity of a pentavalent meningococcal conjugate vaccine containing serogroups A, C, Y, W, and X in healthy adults: a phase 1, single-centre, double-blind, randomised, controlled study. Lancet Infectious Diseases, The, 2018, 18, 1088-1096.	4.6	63
40	Development, Interlaboratory Evaluations, and Application of a Simple, High-Throughput <i>Shigella</i> Serum Bactericidal Assay. MSphere, 2018, 3, .	1.3	31
41	Safety and immunogenicity of an oral tablet norovirus vaccine, a phase I randomized, placebo-controlled trial. JCI Insight, 2018, 3, .	2.3	89
42	Cytokines Are Markers of the Clostridium difficile-Induced Inflammatory Response and Predict Disease Severity. Vaccine Journal, 2017, 24, .	3.2	90
43	Human immune responses against Shigella and enterotoxigenic E. coli : Current advances and the path forward. Vaccine, 2017, 35, 6803-6806.	1.7	22
44	A primary human macrophage-enteroid co-culture model to investigate mucosal gut physiology and host-pathogen interactions. Scientific Reports, 2017, 7, 45270.	1.6	274
45	Functional and Antigen-Specific Serum Antibody Levels as Correlates of Protection against Shigellosis in a Controlled Human Challenge Study. Vaccine Journal, 2017, 24, .	3.2	69
46	A Primary Human Macrophage-Enteroid Co-Culture Model to Investigate Mucosal Gut Physiology and Host-Pathogen Interactions. Gastroenterology, 2017, 152, S56-S57.	0.6	1
47	Tularemia vaccine: Safety, reactogenicity, "Take―skin reactions, and antibody responses following vaccination with a new lot of the Francisella tularensis live vaccine strain – A phase 2 randomized clinical Trial. Vaccine, 2017, 35, 4730-4737.	1.7	30
48	Enterotoxigenic Escherichia coli is phagocytosed by macrophages underlying villus-like intestinal epithelial cells: modeling ex vivo innate immune defenses of the human gut. Gut Microbes, 2017, , 00-00.	4.3	16
49	Bioactive Immune Components of Anti-Diarrheagenic Enterotoxigenic Escherichia coli Hyperimmune Bovine Colostrum Products. Vaccine Journal, 2017, 24, .	3.2	21
50	The Legacy of CVI. Vaccine Journal, 2017, 24, .	3.2	0
51	Randomized, Placebo-Controlled, Double-Blind Phase 2 Trial Comparing the Reactogenicity and Immunogenicity of a Single Standard Dose to Those of a High Dose of CVD 103-HgR Live Attenuated Oral Cholera Vaccine, with Shanchol Inactivated Oral Vaccine as an Open-Label Immunologic Comparator. Vaccine Journal. 2017. 24.	3.2	8
52	lmmunization Coverage Surveys and Linked Biomarker Serosurveys in Three Regions in Ethiopia. PLoS ONE, 2016, 11, e0149970.	1.1	21
53	Springtime for CVI. Vaccine Journal, 2016, 23, 247-247.	3.2	1
54	Serological Monitoring Is Key To Sustain Progress of the Maternal and Neonatal Tetanus Elimination Initiative. Vaccine Journal, 2016, 23, 532-534.	3.2	5

#	Article	IF	CITATIONS
55	Characterization of a multicomponent live, attenuated <i>Shigella flexneri</i> vaccine. Pathogens and Disease, 2016, 74, ftw034.	0.8	15
56	Opsonophagocytic Assay To Evaluate Immunogenicity of Nontyphoidal Salmonella Vaccines. Vaccine Journal, 2016, 23, 520-523.	3.2	11
57	Safety and Immunogenicity of a Parenterally Administered, Structure-Based Rationally Modified Recombinant Staphylococcal Enterotoxin B Protein Vaccine, STEBVax. Vaccine Journal, 2016, 23, 918-925.	3.2	38
58	Live Attenuated Human <i>Salmonella</i> Vaccine Candidates: Tracking the Pathogen in Natural Infection and Stimulation of Host Immunity. EcoSal Plus, 2016, 7, .	2.1	35
59	<i>Salmonella enterica</i> serovar Typhi and gallbladder cancer: a case–control study and metaâ€analysis. Cancer Medicine, 2016, 5, 3310-3235.	1.3	102
60	Maternal immunisation with trivalent inactivated influenza vaccine for prevention of influenza in infants in Mali: a prospective, active-controlled, observer-blind, randomised phase 4 trial. Lancet Infectious Diseases, The, 2016, 16, 1026-1035.	4.6	196
61	Simple method for purification of enterotoxigenic Escherichia coli fimbriae. Protein Expression and Purification, 2016, 119, 130-135.	0.6	4
62	Single-dose Live Oral Cholera Vaccine CVD 103-HgR Protects Against Human Experimental Infection With <i>Vibrio cholerae</i> O1 El Tor. Clinical Infectious Diseases, 2016, 62, 1329-1335.	2.9	154
63	Functional Activity of Antibodies Directed towards Flagellin Proteins of Non-Typhoidal Salmonella. PLoS ONE, 2016, 11, e0151875.	1.1	19
64	Strategies for Coordination of a Serosurvey in Parallel with an Immunization Coverage Survey. American Journal of Tropical Medicine and Hygiene, 2015, 93, 416-424.	0.6	11
65	Safety and Immunogenicity of a Vi Polysaccharide–Tetanus Toxoid Conjugate Vaccine (Typbar-TCV) in Healthy Infants, Children, and Adults in Typhoid Endemic Areas: A Multicenter, 2-Cohort, Open-Label, Double-Blind, Randomized Controlled Phase 3 Study. Clinical Infectious Diseases, 2015, 61, 393-402.	2.9	164
66	<i>Shigella</i> IpaB and IpaD displayed on <i>L. lactis</i> bacteriumâ€like particles induce protective immunity in adult and infant mice. Immunology and Cell Biology, 2015, 93, 641-652.	1.0	43
67	Refined Live Attenuated Salmonella enterica Serovar Typhimurium and Enteritidis Vaccines Mediate Homologous and Heterologous Serogroup Protection in Mice. Infection and Immunity, 2015, 83, 4504-4512.	1.0	10
68	A Bivalent Typhoid Live Vector Vaccine Expressing both Chromosome- and Plasmid-Encoded Yersinia pestis Antigens Fully Protects against Murine Lethal Pulmonary Plague Infection. Infection and Immunity, 2015, 83, 161-172.	1.0	21
69	Vedolizumab affects antibody responses to immunisation selectively in the gastrointestinal tract: randomised controlled trial results. Gut, 2015, 64, 77-83.	6.1	145
70	Safety and Immunogenicity of Single-Dose Live Oral Cholera Vaccine Strain CVD 103-HgR, Prepared from New Master and Working Cell Banks. Vaccine Journal, 2014, 21, 66-73.	3.2	43
71	Helicobacter pylori Infection Affects Immune Responses Following Vaccination of Typhoid-Naive US Adults With Attenuated Salmonella Typhi Oral Vaccine CVD 908-htrA. Journal of Infectious Diseases, 2014, 209, 1452-1458.	1.9	18
72	Live Oral Salmonella enterica Serovar Typhi Vaccines Ty21a and CVD 909 Induce Opsonophagocytic Functional Antibodies in Humans That Cross-React with <i>S</i> . Paratyphi A and <i>S</i> . Paratyphi B. Vaccine Journal, 2014, 21, 427-434.	3.2	52

#	Article	IF	CITATIONS
73	Gut-Homing Conventional Plasmablasts and CD27− Plasmablasts Elicited after a Short Time of Exposure to an Oral Live-Attenuated Shigella Vaccine Candidate in Humans. Frontiers in Immunology, 2014, 5, 374.	2.2	21
74	Serum Bactericidal Assays To Evaluate Typhoidal and Nontyphoidal Salmonella Vaccines. Vaccine Journal, 2014, 21, 712-721.	3.2	62
75	A scalable method for biochemical purification of Salmonella flagellin. Protein Expression and Purification, 2014, 102, 1-7.	0.6	31
76	Intradermal Delivery of <i>Shigella</i> IpaB and IpaD Type III Secretion Proteins: Kinetics of Cell Recruitment and Antigen Uptake, Mucosal and Systemic Immunity, and Protection across Serotypes. Journal of Immunology, 2014, 192, 1630-1640.	0.4	52
77	Age-Dependent Association among Helicobacter pylori Infection, Serum Pepsinogen Levels and Immune Response of Children to Live Oral Cholera Vaccine CVD 103-HgR. PLoS ONE, 2014, 9, e83999.	1.1	14
78	Characterization of systemic and pneumonic murine models of plague infection using a conditionally virulent strain. Comparative Immunology, Microbiology and Infectious Diseases, 2013, 36, 113-128.	0.7	5
79	Safety and tolerability of a live oral Salmonella typhimurium vaccine candidate in SIV-infected nonhuman primates. Vaccine, 2013, 31, 5879-5888.	1.7	19
80	Evaluation of immunogenicity and protective efficacy of orally delivered Shigella type III secretion system proteins IpaB and IpaD. Vaccine, 2013, 31, 2919-2929.	1.7	44
81	Progress and pitfalls in Shigella vaccine research. Nature Reviews Gastroenterology and Hepatology, 2013, 10, 245-255.	8.2	117
82	Safety and Immunogenicity of a Single Oral Dose of Recombinant Double Mutant Heat-Labile Toxin Derived from Enterotoxigenic Escherichia coli. Vaccine Journal, 2013, 20, 1764-1770.	3.2	54
83	Gut Immunology and Oral Vaccination. , 2013, , 59-84.		3
84	Sustained Protection in Mice Immunized with Fractional Doses of Salmonella Enteritidis Core and O Polysaccharide-Flagellin Glycoconjugates. PLoS ONE, 2013, 8, e64680.	1.1	49
85	Broadly Protective Shigella Vaccine Based on Type III Secretion Apparatus Proteins. Infection and Immunity, 2012, 80, 1222-1231.	1.0	124
86	Salmonella enterica Serovar Enteritidis Core O Polysaccharide Conjugated to H:g,m Flagellin as a Candidate Vaccine for Protection against Invasive Infection with <i>S.</i> Enteritidis. Infection and Immunity, 2011, 79, 4240-4249.	1.0	114
87	Immunology of gut mucosal vaccines. Immunological Reviews, 2011, 239, 125-148.	2.8	207
88	Oral priming with Salmonella Typhi vaccine strain CVD 909 followed by parenteral boost with the S. Typhi Vi capsular polysaccharide vaccine induces CD27+lgDâ^' S. Typhi-specific IgA and IgG B memory cells in humans. Clinical Immunology, 2011, 138, 187-200.	1.4	56
89	Mucosal IgA Responses in Healthy Adult Volunteers following Intranasal Spray Delivery of a Live Attenuated Measles Vaccine. Vaccine Journal, 2011, 18, 355-361.	3.2	26
90	Engineering and Preclinical Evaluation of Attenuated Nontyphoidal Salmonella Strains Serving as Live Oral Vaccines and as Reagent Strains. Infection and Immunity, 2011, 79, 4175-4185.	1.0	89

#	Article	IF	CITATIONS
91	Cell-Associated Flagella Enhance the Protection Conferred by Mucosally-Administered Attenuated Salmonella Paratyphi A Vaccines. PLoS Neglected Tropical Diseases, 2011, 5, e1373.	1.3	48
92	Adjuvanted Intranasal Norwalk Virusâ€Like Particle Vaccine Elicits Antibodies and Antibodyâ€Secreting Cells That Express Homing Receptors for Mucosal and Peripheral Lymphoid Tissues. Journal of Infectious Diseases, 2010, 202, 1649-1658.	1.9	200
93	A New Generation of Stable, Nonantibiotic, Low-Copy-Number Plasmids Improves Immune Responses to Foreign Antigens in <i>Salmonella enterica</i> Serovar Typhi Live Vectors. Infection and Immunity, 2010, 78, 337-347.	1.0	38
94	Measles DNA vaccine priming for young infants. Procedia in Vaccinology, 2010, 2, 151-158.	0.4	1
95	Mucosally DeliveredSalmonellaTyphi Expressing theYersinia pestisF1 Antigen Elicits Mucosal and Systemic Immunity Early in Life and Primes the Neonatal Immune System for a Vigorous Anamnestic Response to Parenteral F1 Boost. Journal of Immunology, 2009, 182, 1211-1222.	0.4	24
96	Mucosal Immunization with Attenuated <i>Salmonella enterica</i> Serovar Typhi Expressing Protective Antigen of Anthrax Toxin (PA83) Primes Monkeys for Accelerated Serum Antibody Responses to Parenteral PA83 Vaccine. Journal of Infectious Diseases, 2009, 199, 326-335.	1.9	38
97	Sindbis Virus-Based Measles DNA Vaccines Protect Cotton Rats against Respiratory Measles: Relevance of Antibodies, Mucosal and Systemic Antibody-Secreting Cells, Memory B Cells, and Th1-Type Cytokines as Correlates of Immunity. Journal of Virology, 2009, 83, 2789-2794.	1.5	22
98	<i>Salmonella enterica</i> serovar Typhi live vector vaccines finally come of age. Immunology and Cell Biology, 2009, 87, 400-412.	1.0	77
99	An improved Francisella tularensis live vaccine strain (LVS) is well tolerated and highly immunogenic when administered to rabbits in escalating doses using various immunization routes. Vaccine, 2008, 26, 1773-1785.	1.7	48
100	Preclinical Safety and Biodistribution of Sindbis Virus Measles DNA Vaccines Administered as a Single Dose or Followed by Live Attenuated Measles Vaccine in a Heterologous Prime–Boost Regimen. Human Gene Therapy, 2008, 19, 522-531.	1.4	10
101	Safety and Immunogenicity of CVD 1208S, a Live, Oral <i>Ĵ"guaBA Δsen Δset Shigella flexneri</i> 2a Vaccine Grown on Animal-Free Media. Hum Vaccin, 2007, 3, 268-275.	2.4	72
102	Clinical trials of Shigella vaccines: two steps forward and one step back on a long, hard road. Nature Reviews Microbiology, 2007, 5, 540-553.	13.6	303
103	Measurement of Tetanus Antitoxin in Oral Fluid. Pediatric Infectious Disease Journal, 2006, 25, 819-825.	1.1	27
104	Neonatal Immunization with a Sindbis Virus-DNA Measles Vaccine Induces Adult-Like Neutralizing Antibodies and Cell-Mediated Immunity in the Presence of Maternal Antibodies. Journal of Immunology, 2006, 176, 5671-5681.	0.4	44
105	Characterization of Immune Responses Induced by Intramuscular Vaccination with DNA Vaccines Encoding Measles Virus Hemagglutinin and/or Fusion Proteins. Journal of Virology, 2005, 79, 9854-9861.	1.5	29
106	A SEROSURVEY TO IDENTIFY THE WINDOW OF VULNERABILITY TO WILD-TYPE MEASLES AMONG INFANTS IN RURAL MALI. American Journal of Tropical Medicine and Hygiene, 2005, 73, 26-31.	0.6	38
107	A serosurvey to identify the window of vulnerability to wild-type measles among infants in rural Mali. American Journal of Tropical Medicine and Hygiene, 2005, 73, 26-31.	0.6	15
108	Deletion in theShigellaEnterotoxin Genes Further AttenuatesShigella flexneri2a Bearing Guanine Auxotrophy in a Phase 1 Trial of CVD 1204 and CVD 1208. Journal of Infectious Diseases, 2004, 190, 1745-1754.	1.9	86

#	Article	IF	CITATIONS
109	Immune Responses to an Oral Typhoid Vaccine Strain That Is Modified to Constitutively Express Vi Capsular Polysaccharide. Journal of Infectious Diseases, 2004, 190, 565-570.	1.9	68
110	Adaptation of the Endogenous Salmonella enterica Serovar Typhi clyA -Encoded Hemolysin for Antigen Export Enhances the Immunogenicity of Anthrax Protective Antigen Domain 4 Expressed by the Attenuated Live-Vector Vaccine Strain CVD 908- htrA. Infection and Immunity, 2004, 72, 7096-7106.	1.0	67
111	Immunogenicity of recombinant LT-B delivered orally to humans in transgenic corn. Vaccine, 2004, 22, 4385-4389.	1.7	163
112	Animal models paving the way for clinical trials of attenuated Salmonella enterica serovar Typhi live oral vaccines and live vectors. Vaccine, 2003, 21, 401-418.	1.7	91
113	Attenuated Salmonella enterica Serovar Typhi and Shigella flexneri 2a Strains Mucosally Deliver DNA Vaccines Encoding Measles Virus Hemagglutinin, Inducing Specific Immune Responses and Protection in Cotton Rats. Journal of Virology, 2003, 77, 5209-5217.	1.5	72
114	Concomitant Induction of CD4+ and CD8+ T Cell Responses in Volunteers Immunized with <i>Salmonella enterica</i> Serovar Typhi Strain CVD 908-htrA. Journal of Immunology, 2003, 170, 2734-2741.	0.4	94
115	Characterization of CD8+ Effector T Cell Responses in Volunteers Immunized with <i>Salmonella enterica</i> Serovar Typhi Strain Ty21a Typhoid Vaccine. Journal of Immunology, 2002, 169, 2196-2203.	0.4	139
116	Salmonella enterica Serovar Typhi Live Vector Vaccines Delivered Intranasally Elicit Regional and Systemic Specific CD8+ Major Histocompatibility Class I-Restricted Cytotoxic T Lymphocytes. Infection and Immunity, 2002, 70, 4009-4018.	1.0	24
117	Construction, Genotypic and Phenotypic Characterization, and Immunogenicity of Attenuated Δ guaBA Salmonella enterica Serovar Typhi Strain CVD 915. Infection and Immunity, 2001, 69, 4734-4741.	1.0	49
118	In Vivo Characterization of the Murine Intranasal Model for Assessing the Immunogenicity of Attenuated <i>Salmonella enterica</i> Serovar Typhi Strains as Live Mucosal Vaccines and as Live Vectors. Infection and Immunity, 2000, 68, 205-213.	1.0	79
119	A comparison of immunogenicity and in vivo distribution of Salmonella enterica serovar Typhi and Typhimurium live vector vaccines delivered by mucosal routes in the murine model. Vaccine, 2000, 18, 3208-3213.	1.7	39
120	Attenuated ΔguaBA Salmonella typhi Vaccine Strain CVD 915 as a Live Vector Utilizing Prokaryotic or Eukaryotic Expression Systems to Deliver Foreign Antigens and Elicit Immune Responses. Clinical Immunology, 1999, 92, 76-89.	1.4	67
121	Live Attenuated Vectors: Have they Delivered?. , 0, , 72-86.		О